Drug Trial Radar · NCT04607421
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
841
Actual
Start
Dec 21, 2020
Primary completion
Mar 1, 2025
Study completion Jul 29, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Ono Pharmaceutical Co., Ltd.; Merck KGaA, Darmstadt, Germany; Eli Lilly and Company
- First posted
- Oct 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: * has spread to other parts of the body (metastatic); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. Participants in this study will receive one of the following study treatments: * Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection into the vein) at the study clinic. * Encorafenib plus cetuximab with chemotherapy: These participants will receive encorafenib and cetuximab in the way described in the bullet above. Additionally, they will receive standard chemotherapy by IV infusion and oral treatment at home. * Chemotherapy alone: These participants will receive chemotherapy, the standard treatment for this condition, by IV infusion at the study clinics and oral treatment at home. This study is currently enrolling participants who will receive either encorafenib plus cetuximab with chemotherapy or chemotherapy alone. The study team will monitor how each participant responds to the study treatment for up to about 3 years.
Conditions
- Neoplasms
Interventions
EncorafenibDrug
75 mg capsules
CetuximabDrug
Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
OxaliplatinDrug
Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
IrinotecanDrug
Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
LeucovorinDrug
Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
5-FUDrug
Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
CapecitabineDrug
150 mg or 500 mg Tablet
BevacizumabDrug
Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- SLI: Number of Participants With Dose Limiting Toxicity (DLTs)Time frame: Cycle 1 (28 days)
- Phase 3: Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) for Arm B vs Arm C - FASTime frame: From date of randomization to earliest documentation of PD by BICR or death or censoring date, whichever occurred first (maximum up to 37.25 months)
- Phase 3: Objective Response Rate (ORR) as Assessed by BICR for Arm B vs Arm C - FAS ORR SubsetTime frame: From date of randomization to until documented PD by BICR, or start of subsequent anticancer therapy or death, whichever occurred first (maximum up to 24.71 months)
- Cohort 3: ORR as Assessed by BICR for Arm D vs Arm E - FASTime frame: From date of randomization until documented PD by BICR, or start of subsequent anticancer therapy or death, whichever occurred first (maximum up to 14.1 months)
Locations
274 sites in 29 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
Mayo Clinic in Arizona - Scottsdale
Scottsdale, Arizona
Keck Hospital of USC
Los Angeles, California
LAC & USC Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
USC/Norris Comprehensive Cancer Center/Investigational Drug Services
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Keck Hospital of USC Pasadena
Pasadena, California
Mount Sinai Comprehensive Cancer Center, Aventura
Aventura, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Mount Sinai Medical Center
Miami Beach, Florida
BRCR Global
Plantation, Florida
BRCR Medical Center Inc.
Plantation, Florida
UChicago Medicine - River East
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
UChicago Medicine at Ingalls - Flossmoor
Flossmoor, Illinois
UChicago Medicine Ingalls Memorial
Harvey, Illinois
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois
The University of Chicago Medicine Center for Advanced Care Orland Park
Orland Park, Illinois
UChicago Medicine at Ingalls - Tinley Park
Tinley Park, Illinois
Ochsner Clinic Foundation
New Orleans, Louisiana
Mayo Clinic Rochester
Rochester, Minnesota
Siteman Cancer Center - St Peters
City of Saint Peters, Missouri
Siteman Cancer Center - West County
Creve Coeur, Missouri
Siteman Cancer Center - North County
Florissant, Missouri
Barnes- Jewish Hospital
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Siteman Cancer Center - South County
St Louis, Missouri
Oncology Hematology West PC dba Nebraska Cancer Specialists
Omaha, Nebraska
Oncology Hematology West PC dba Nebraska Cancer Specialists
Omaha, Nebraska
Oncology Hematology West PC dba Nebraska Cancer Specialists
Omaha, Nebraska
Oncology Hematology West PC dba Nebraska Cancer Specialists
Papillion, Nebraska
Memorial Sloan Kettering Cancer Center - Basking Ridge
Basking Ridge, New Jersey
Summit Medical Group
Berkeley Heights, New Jersey
Summit Medical Group
Florham Park, New Jersey
Memorial Sloan Kettering Cancer Center- Monmouth
Middletown, New Jersey
Memorial Sloan Kettering Cancer Center- Bergen
Montvale, New Jersey
Memorial Sloan Kettering Cancer Center Commack
Commack, New York
Memorial Sloan Kettering Cancer Center - Westchester
Harrison, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Showing 40 of 274 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.